Bcl9L Antibody
| Code | Size | Price |
|---|
| PSI-6213-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6213-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Bcl9L Antibody: BCL9-2, DLNB11, Protein BCL9-2, B-cell lymphoma 9-like protein
Application Note:
Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL and immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.
Background References:
- Katoh M and Katoh M. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico. Int. J. Mol. Med. 2003; 12:643-9.
- Adachi S, Jigami T, Yasui T, et al. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res. 2004; 64:8496-501.
- Toya H, Oyama T, Ohwada S, et al. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. Cancer Sci. 2007; 98:484-90.
- Deka J, Wiedemann N, Anderle P, et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinoma. Cancer Res. 2010; 70:6619-28.
Buffer:
Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (100%), Rat: (100%)
Immunogen:
Bcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L.
The immunogen is located within amino acids 20 - 70 of Bcl9L.
The immunogen is located within amino acids 20 - 70 of Bcl9L.
NCBI Gene ID #:
283149
NCBI Official Name:
B-cell CLL/lymphoma 9-like
NCBI Official Symbol:
BCL9L
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 165 kDa
Observed: 195 kDa
Observed: 195 kDa
Protein Accession #:
NP_872363
Protein GI Number:
32698936
Purification:
Bcl9L Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.
Swissprot #:
Q86UU0
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | Bcl9L Peptide | PSI-6213P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|